Novo Nordisk Sues Hims to Stop Semaglutide Copycats
Lead On February 9, 2026, Danish drugmaker Novo Nordisk filed a U.S. lawsuit against Hims & Hers Health Inc., saying the company copied its semaglutide-based obesity medicines. The complaint targets both an attempted copycat pill strategy and injectable products that, Novo alleges, mimic Wegovy and Ozempic. Hims had recently abandoned plans to market a pill … Read more